NCT06998628RecruitingPhase 2
Pentoxifylline as Anti-Inflammatory in Patients With Rheumatoid Arthritis
Clinical Study Evaluating the Effect of Pentoxifylline as Anti Inflammatory in Patients With Rheumatoid Arthritis
Source: ClinicalTrials.gov · Last updated 5 Oct 2026
Brief summary (registry, in English)
Rheumatoid arthritis (RA) is a long-term inflammatory condition that leads to gradual damage of joints lined by synovial membranes, along with various potential effects outside of the joints. While RA can affect any joint, it typically involves the metacarpophalangeal, proximal interphalangeal, and metatarsophalangeal joints, as well as the wrists and knees. Symptoms related to the joints and surrounding tissues include swelling, tenderness upon touch, morning stiffness, and significant difficulty moving the affected joints
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 22 May 2025
- Start date
- 2 Jun 2025
- Primary completion date
- 30 May 2027
- Lead sponsor
- Tanta University
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT06998628
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 50
- From 2 Jun 2025 to the primary completion date, 30 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving biological or synthetic DMARDs
Other illness
- Patients with retinal or cerebral hemorrhage.
- Patients with hypersensitivity to study medications.
Other
- Patients with renal and hepatic dysfunction.
- Pregnant and lactating females.
Who the study is looking for
- Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) \[9\] i.e., 28 joints disease activity score (DAS 28) \>2.6.
- Patients receiving the conventional DMARDs.
- Both sexes.
- Age range between 18and 70 years old
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Faculty of Medicine, Al-Azhar University Coordinator of this site? Confirm its status | Damietta | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.